Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as a solution for injection for intravenous use. It treats metastatic colorectal cancer and is used as adjuvant therapy in colorectal cancer patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan Accord is a topoisomerase I inhibitor indicated for colorectal cancer treatment pathways.

- Metastatic colorectal cancer: improves overall survival and disease control. - Adjuvant treatment of colorectal cancer: reduces risk of postoperative recurrence. - Colorectal cancer combination therapy: used with other agents to enhance tumor response.

Irinotecan Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: may be mitigated with anti‑emetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness. - Abdominal pain: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent treatment. - Severe colitis: life‑threatening diarrhea with possible dehydration. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: rare arrhythmias or myocardial ischemia. - Secondary malignancies: very rare risk of therapy‑related cancers.

When using Irinotecan Accord, clinicians should observe several safety measures.

- Pregnancy: Category D – avoid use unless potential benefits justify the risk. - Renal impairment: assess kidney function and adjust dose as needed. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Myelosuppression: perform regular complete blood counts to detect neutropenia. - Drug interactions: avoid concurrent strong CYP3A4 inhibitors that may increase exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase SN‑38 levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Other topoisomerase I inhibitors: additive toxicity risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise exposure. - Anticoagulants (e.g., warfarin): monitor INR for bleeding risk. - Concurrent myelosuppressive agents: increase risk of severe neutropenia.